Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy

British Journal of Urology

Volumn 80, Issue 1, 1997, Pages 78-83

  Kurita, Y ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiandrogen; Benign prostatic hyperplasia; Prostate specific antigen density; Transition zone; blocker

Indexed keywords

ALLYLESTRENOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIANDROGEN; PERSELIN; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORRELATION FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TRANSRECTAL ULTRASONOGRAPHY; URINE FLOW RATE; UROFLOWMETRY;

EID: 0031396769     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1997.00232.x     Document Type: Article

References (19)

1. McConnell JD. Barry MJ. Bruskewitz RC el al. Benign prostatic hyperplasia: diagnosis and treatment. Clinical Practice Guidline Number 8. AHCPR Publication No. 94-0582. Rockvill: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services 1994
2. Kawabe K, Ueno A, Takimoto Y, Aso Y. Kato H and YM617 clinical study group. Use of an od-blocker, YM617. in the treatment of benign prostatic hypertrophy. J Vrol 1990: 144: 908-12
3. Sarkar SL, Jogi KV. Estrenols and male sex organs -Part 1 Effect of a few structurally related 19-nortestosterone delivatives on sex organs of adult male albino rats. Indian ) MedRes 1971; 59: 768-73
4. Shida K, Koyanagi T, Kawakura K et al. Clinical effects of allylestrenol on benign prostatic hypertrophy by doubleblind method. Ada Urol]pn 1986; 32: 625-48 (in Japanese)
5. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Vrol Clin North Am 1990; 17: 477-86
6. Barry MJ, Fowler F] Jr, O'Leary MP et at. and the Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Vrol 1992; 148: 1549-77
7. Coffey DS, Walsh PC. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin N Am 1990; 17:461-75
8. Wilson JD. The pathogenesis of benign prostatic hyperplasia. Am] Med 1980; 68: 745-56
9. Tempany CMC, Partin AW, Zerhouni EA, Zinreich SJ, Walsh PC. The influence of flnasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. Prostate 1993; 22: 39-42
10. Tewari A, Shinohara K, Narayan P. Transition zone volume and transition zone ratio: predictor of uroflow response to flnasteride therapy in benign prostatic hyperplasia patients. Urology 1995; 45: 258-65
11. Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992; 21: 297-307
12. Kaplan SA, Te AE. Pressler LB, Olsson CA. Transition zone index as a method of assessing benign prostatic hyperplasia: correlation with symptoms, urine flow and detrusor pressureJ Urol 1995; 154: 1764-9
13. 3 Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159-63
14. Abrahamsson P-A. Lija H, Falkmer S. Wadstrom LB. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 1988; 12: 39-46
15. 5 Weber JP. Oesterling JE, Peters CA. Partin AW, Chan DW. Walsh PC. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J Urol 1989; 141: 987-92
16. Lepor H, Wang B. Shapiro E. Relationship between prostatic epithelial volume and serum prostate-specific antigen levels. Urology 1994: 44: 199-205
17. Benson MC, Whang IS, Olsson CA, McMahon DJ. Looner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147: 817-21
18. Harada M, Kinoshita Y. Moriyama M et al. Histological evaluation of benign prostatic hyperplasia treated by longterm administration of chlormadinone acetate (CMA). Prostate 1994: 25: 147-55
19. Drach GW, Layton TN, Binard WJ. Male peak urinary flow rate: relationships to volume voided and age. J Urol 1979: 122: 210-21